Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP) has announced the appointments of Dr. Robert Langer and Dr. Stephen Brannan to its Scientific Advisory Board, bolstering its expertise in biotechnology, drug delivery, and central nervous system clinical development. The company is advancing a pipeline of novel serotonergic agonists (NSAs) designed to activate serotonin pathways and promote neuroplasticity, targeting major depressive disorder (MDD) and generalized anxiety disorder (GAD).
Dr. Langer, a professor at MIT and a pioneer in drug delivery systems, brings decades of experience in biotechnology innovation. Dr. Brannan, a psychiatrist and former Chief Medical Officer at several biopharmaceutical companies, adds deep clinical development expertise in CNS disorders. Their appointments underscore Helus Pharma's commitment to disciplined, evidence-based drug development as it addresses unmet needs in mental health.
Helus Pharma is currently advancing HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of MDD, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004, another proprietary NSA, is in Phase 2 for GAD. The company also maintains an extensive research portfolio of investigational NSAs.
"We are honored to welcome Dr. Langer and Dr. Brannan to our Scientific Advisory Board," said Doug Drysdale, Chief Executive Officer of Helus Pharma. "Their unparalleled expertise will be invaluable as we continue to develop our pipeline of novel serotonergic agonists and work to improve treatment outcomes for individuals suffering from mental health conditions."
The appointments come as Helus Pharma aims to improve the treatment landscape through NSAs that provide durable improvements in mental health. The company operates in Canada, the United States, the United Kingdom, and Ireland. For more information, visit the company's newsroom at https://ibn.fm/HELP or the company's website at www.helus.com.
